Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma

Allergy and Asthma Proceedings

Volumn 35, Issue 5, 2014, Pages e72-e79

  Ciebiada, MacIej ^a   Domagała, Mateusz ^a   Gorska Ciebiada, Małgorzata ^a   Gorski, Paweł ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E;

ADULT; AIRWAY OBSTRUCTION; ALLERGIC RHINITIS; ALLERGY; ARTIFICIAL VENTILATION; ASTHMA; ATOPIC DERMATITIS; ATOPY; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERSISTENT AIRWAYS OBSTRUCTION; PRICK TEST; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RESPIRATORY FAILURE; SMOKING; SPIROMETRY; DISEASE COURSE; LUNG FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; AIRWAY OBSTRUCTION; ASTHMA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84907048189     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3785     Document Type: Conference Paper

References (24)

1. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2012. Available from: http//www.ginasthma.org/.
2. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 58:322-327, 2003.
3. Lee T, Lee YS, Bae YJ, et al. Smoking, longer disease duration and absence of rhinosinusitis are related to fixed airway obstruction in Koreans with severe asthma: findings from the COREA study. Respir Res 12:1, 2011.
4. Hwang YI, Kim CH, Kang HR, et al. Comparison of the prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio criteria. J Korean Med Sci 24:621-626, 2009.
5. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 162: 2341-2351, 2000.
6. ten Brinke A. Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 8:63-69, 2008.
7. Dougherty RH, and Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation prone phenotype. Clin Exp Allergy 39:193-202, 2009.
8. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) 2011. From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcpd.org/.
9. Gaga M, Papageorgiou N, Yiourgioti G, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 35:954-959, 2005.
10. Brightling CE. Eosinophils, bronchitis and asthma: pathogenesis of cough and airflow obstruction. Pulm Pharmacol Then 24:324-327, 2011.
11. Tsoumakidou M, Tzanakis N, Kyriakou D, et al. Inflammatory cell profiles and T-lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma. Clin Exp Allergy 34:234-240, 2004.
12. Koga T, Oshita Y, Kamimura T, et al. Characterisation of patients with frequent exacerbation of asthma. Respir Med 100: 273-278, 2006.
13. Lee JH, Haselkorn T, Borish L, et al. Risk factors associated with persistent airflow limitation in severe or difficult to treat asthma: insights from the TENOR study. Chest 132:1882-1889, 2007.
14. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS task force. Standardisation of spirometry. Eur Respir J 26:319-338, 2005.
15. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171:912-930, 2005.
16. EAACI Position Paper. Skin tests used in type I allergy testing. Position paper. Sub-Committee on Skin Tests of the European Academy of Allergology and Clinical Immunology. Allergy 44:1-59, 1989.
17. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 126:466-476, 2010.
18. Fish JE, and Peters SP. Airway remodeling and persistent airway obstruction in asthma. J Allergy Clin Immunol 104:509-516, 1999.
19. Davies DE. The role of the epithelium in airway remodeling in asthma. Proc Am Thorac Soc 6:678-682, 2009.
20. Brightling CE, Gupta S, Gonem S, et al. Lung damage and airway remodelling in severe asthma. Clin Exp Allergy 42:638-649, 2012.
21. Agache I, and Ciobanu C. Predictive value of lung function trend and FeNO for difficult asthma in children. J Investig Allergol Clin Immunol 22:419-426, 2012.
22. Ohkura N, Fujimura M, Tokuda A, et al. Evaluation of airway hyperresponsiveness and exhaled nitric oxide as risk factors for airway remodeling in patients with stable asthma. Allergy Asthma Proc 30:419-423, 2009.
23. Damera G, and Panettieri R. Irreversible airway obstruction in asthma: what we lose, we lose early. Allergy Asthma Proc 35:111-118, 2014.
24. Black PN, Udy AA, and Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 55:501-504, 2000.